Unusual infectious complications of dermatologic procedures

Dermatologic Clinics

Volumn 21, Issue 2, 2003, Pages 321-335

  Garman, Mary E ^a   Orengo, Ida ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CARBAPENEM; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CLOTRIMAZOLE; DIPHTHERIA ANTIBODY; DIPHTHERIA VACCINE; DOXYCYCLINE; FAMCICLOVIR; FLUCONAZOLE; IMIPENEM; KETOCONAZOLE; MACROLIDE; MONOBACTAM; NAFCILLIN; NYSTATIN; OXACILLIN; PENICILLIN DERIVATIVE; PENTAMIDINE ISETHIONATE; QUINOLONE; STIBOGLUCONATE SODIUM; SULFONAMIDE; VALACICLOVIR;

ANTIBIOTIC THERAPY; ASPERGILLUS FLAVUS; CANDIDA; CLINICAL FEATURE; CORYNEBACTERIUM DIPHTHERIAE; DEBRIDEMENT; DERMATOMYCOSIS; DIPHTHERIA; ENTEROBACTER INFECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HYPERBARIC OXYGEN; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; NECROTIZING FASCIITIS; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SKIN LEISHMANIASIS; SKIN SURGERY; TOXIC SHOCK SYNDROME;

EID: 0038747205     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(02)00097-9     Document Type: Review

References (111)

1. Kernodle DS, Kaise AB. Postoperative infections and antimicrobial prophylaxis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell: principles and practice of infectious disease. 5th edition. New York (NY): Churchill Livingstone; 2000. p. 3177-91.
2. Francoeur JR. Joseph Lister: surgeon scientist (1827-1912). J Invest Surg 2000;13:129-32.
3. Dellinger EP. Surgical infections and choice of antibiotics. In: Townsend CM, Beauchamp DR, Evers MB, Mattox KL, Sabiston DC, editors. Sabiston textbook of surgery: the biological basis of modern surgical practice. Philadelphia (PA): WB Saunders; 2001. p. 171-88.
4. Haas AF, Grekin RC. Antibiotic prophylaxis in dermatologic surgery. J Am Acad Dermatol 1995;32:155-76.
5. Futoryan T, Grande D. Postoperative wound infection rates in dermatologic surgery. Dermatol Surg 1995;21:509-14.
6. Cruse PJE, Foord R. A five-year prospective study of 23,649 surgical wounds. Arch Surg 1973;107:206-10.
7. 2 laser resurfacing and occlusive dressing use. Dermatol Surg 2000;26:32-6.
8. Ross EV, Amesbury EC, Barile A, et al. Incidence of postoperative infection or positive blood culture after facial laser surgery: a pilot study, a case report, and a proposal for a rational approach to antibiotic prophylaxis. J Am Acad Dermatol 1998;39:975-81.
9. Sriprachya-Anunt S, Fitzpatrick RE, Goldman MP, et al. Infections complicating pulsed carbon dioxide laser resurfacing for photoaged facial skin. Dermatol Surg 1997;23:527-35.
10. 2 laser resurfacing infection rate with and without prophylactic antibiotics. Dermatol Surg 1999;25:857-61.
11. Schlievert PM, Bohach GA, Ohlendorf DH. Molecular structure of staphylococcus and streptococcus superantigens. J Clin Immunol 1995;15(Suppl 6):4S-10S.
12. Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1998;39:383-98.
13. Bosley AR, Bluett NH, Sowden G. Toxic shock syndrome after elective minor dermatological surgery. BMJ 1993;306:386-7.
14. Huntley AC, Tanabe JL. Toxic shock syndrome as a complication of dermatologic surgery. J Am Acad Dermatol 1987;16(1 Pt 2):227-9.
15. Dmytryshyn JR, Gribble MJ, Kassen BO. Chemical face peel complicated by toxic shock syndrome. A case report. Arch Otolaryngol 1983;109:170-1.
16. Lo Verme WE, Drapkin MS, Courtiss EH, et al. Toxic shock syndrome after chemical face peel. Plast Reconstr Surg 1987;80:115-8.
17. Apfelberg DB. A critical appraisal of high-energy pulsed carbon dioxide laser facial resurfacing for acne scars. Ann Plast Surg 1997;38:95-100.
18. Rhee CA, Smith RJ, Jackson IT. Toxic shock syndrome associated with suction-assisted lipectomy. Aesthetic Plast Surg 1994;18:161-3.
19. Umeda T, Ohara H, Hayashi O, et al. Toxic shock syndrome after suction lipectomy. Plast Reconstr Surg 2000;106:204-7.
20. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992;14:2-11.
21. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1-7.
22. Todd J, Fishaut M, Kapral F, et al. Toxic-shock syndrome associated with phage-group-1 staphylococci. Lancet 1978;2:1116-8.
23. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep 1997;46:1-55.
24. Centers for Disease Control and Prevention. Epidemiology Program Office, Division of Public Health Surveillance and Informantics: case definitions for infectious conditions under public health surveillance. Part 1. Case definitions for nationally notifiable infectious disease. Available at: http://www.cdc.gov/epo/dphsi/casedef/notifiable.htm. Accessed July 18, 2001.
25. Davis JP, Chesney PJ, Wand PJ, et al. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 1980;303:1429-35.
26. Davis JP, Osterholm MT, Helms CM, et al. Tri-state toxic-shock syndrome study. II. Clinical and laboratory findings. J Infect Dis 1982;145:441-8.
27. Wadvogel FA. Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell: principles and practice of infectious disease. 5th edition. New York (NY): Churchill Livingstone; 2000. p. 2069-92.
28. Paris AL, Herwaldt LA, Blum D, et al. Pathologic findings in twelve fatal cases of toxic shock syndrome. Ann Intern Med 1982;96:852-7.
29. Todd JK. Therapy of toxic shock syndrome. Drugs 1990;39:856-61.
30. Descamps V, Aitken J, Lee MG. Hippocrates on necrotising fasciitis. Lancet 1994;344:556.
31. Wilson B. Necrotizing fasciitis. Am Surg 1952;18:416-31.
32. Green RJ, Dafoe DC, Raffin TA. Necrotizing fasciitis. Chest 1996;110:219-29.
33. McHenry CR, Piotrowski JJ, Petrinic D, et al. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995;221:558-63.
34. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996;334:240-5.
35. Latimer PR, Hodgkins PR, Vakalis AN, et al. Necrotising fasciitis as a complication of botulinum toxin injection. Eye 1998;12(Pt 1):51-3.
36. Alexander J, Takeda D, Sanders G, et al. Fatal necrotizing fasciitis following suction-assisted lipectomy. Ann Plast Surg 1988;20:562-5.
37. Barillo DJ, Cancio LC, Kim SH, et al. Fatal and nearfatal complications of liposuction. South Med J 1998;91:487-92.
38. Gibbons MD, Lim RB, Carter PL. Necrotizing fasciitis after tumescent liposuction. Am Surg 1998;64:458-60.
39. Jordan DR, Mawn L, Marshall DH. Necrotizing fasciitis caused by group A streptococcus infection after laser blepharoplasty. Am J Ophthalmol 1998;125:265-6.
40. Ray AM, Bressler K, Davis RE, et al. Cervicofacial necrotizing fasciitis. A devastating complication of blepharoplasty. Arch Otolaryngol Head Neck Surg 1997;123:633-6.
41. Suner IJ, Meldrum ML, Johnson TE, et al. Necrotizing fasciitis after cosmetic blepharoplasty. Am J Ophthalmol 1999;128:367-8.
42. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996;335:547-54.
43. Zittergruen M, Grose C. Magnetic resonance imaging for early diagnosis of necrotizing fasciitis. Pediatr Emerg Care 1993;9:26-8.
44. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med 1984;310:1689-93.
45. Burge TS. Necrotizing fasciitis - the hazards of delay. J R Soc Med 1995;88:342P-3P.
46. Brown DR, Davis NL, Lepawsky M, et al. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg 1994;167:485-9.
47. Riseman JA, Zamboni WA, Curtis A, et al. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 1990;108:847-50.
48. Roth RR, James WD. Microbiology of the skin: resident flora, ecology, infection. J Am Acad Dermatol 1989;20:367-90.
49. Rendon-Pellerano MI, Lentini J, Eaglstein WE, et al. Laser resurfacing: usual and unusual complications. Dermatol Surg 1999;25:360-6.
50. Pandit N, Yeshwanth M. Cutaneous diphtheria in a child. Int J Dermatol 1999;38:298-305.
51. Adriaans B. Cutaneous diphtheria. In: Canizares O, Harman R, editors. Clinical tropical dermatology. 2nd edition. Boston (MA): Blackwell Scientific; 1992. p. 231-3.
52. Kain KC. Skin lesions in returned travelers. Med Clin N Am 1999;83:1077-102.
53. Hofler W. Cutaneous diphtheria. Int J Dermatol 1991;30:845-7.
54. Monsuez JJ, Mathieu D, Arnout F, et al. Cutaneous diphtheria in a homeless man. Lancet 1995;346:649-50.
55. Magill AJ. Fever in the returned traveler. Infect Dis Clin N Am 1998;12:445-69.
56. Runyon EH. Pathogenic mycobacteria. Bibl Tuberc 1965;21:235-87.
57. American Thoracic Society, Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156:S1-25.
58. Wallace Jr RJ, Swenson JM, Silcox VA, et al. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983;5:657-79.
59. Hautmann G, Lotti T. Atypical mycobacterial infections of the skin. Dermatol Clin 1994;12:657-68.
60. Wallace Jr RJ, Tanner D, Brennan PJ, et al. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993;119:482-6.
61. Grange JM. Mycobacterium chelonei. Tubercle 1981;62:273-6.
62. Wallace Jr RJ, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992;166:405-12.
63. Saluja A, Peters NT, Lowe L, et al. A surgical wound infection due to Mycobacterium chelonae successfully treated with clarithromycin. Dermatol Surg 1997;23:539-43.
64. Centers for Disease Control and Prevention. Rapidly growing mycobacterial infection following liposuction and liposculpture - Caracas, Venezuela, 1996-1998. MMWR Morb Mortal Wkly Rep 1998;47:1065-7.
65. Kevitch R, Guyuron B. Mycobacterial infection following blepharoplasty. Aesthetic Plast Surg 1991;15:229-32.
66. Moorthy RS, Rao NA. Atypical mycobacterial wound infection after blepharoplasty. Br J Ophthalmol 1995;79:93.
67. Weitzul S, Eichhorn PJ, Pandya AG. Nontuberculous mycobacterial infections of the skin. Dermatol Clin 2000;18:359-77.
68. Brown BA, Wallace Jr RJ, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992;36:180-4.
69. McCracken D, Flanagan P, Hill D, et al. Cluster of cases of Mycobacterium chelonae bacteraemia. Eur J Clin Microbiol Infect Dis 2000;19:43-6.
70. Swenson JM, Wallace Jr RJ, Silcox VA, et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985;28:807-11.
71. Ozluer SM, De'Ambyyrosis BJ. Mycobacterium abscessus wound infection. Australas J Dermatol 2001;42:26-9.
72. Chadha R, Grover M, Sharma A, et al. An outbreak of post-surgical wound infections due to Mycobacterium abscessus. Pediatr Surg Int 1998;13:406-10.
73. Safranek TJ, Jarvis WR, Carson LA, et al. Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution. N Engl J Med 1987;317:197-201.
74. Foz A, Roy C, Jurado J, et al. Mycobacterum chelonei iatrogenic infections. J Clin Microbiol 1978;7:319-21.
75. Rodriguez G, Ortegon M, Camargo D, et al. Iatrogenic Mycobacterium abscessus infection: histopathology of 71 patients. Br J Dermatol 1997;137:214-8.
76. Villanueva A, Calderon RV, Vargas BA, et al. Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. Clin Infect Dis 1997;24:1147-53.
77. Murillo J, Torres J, Bofill L, et al. Skin and wound infection by rapidly growing mycobacteria: an unexpected complication of liposuction and liposculpture. Arch Dermatol 2000;136:1347-52.
78. Mushatt DM, Witzig RS. Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin. Clin Infect Dis 1995;20:1441-2.
79. Behroozan DS, Christian MM, Moy RL. Mycobacterium fortuitum infection following neck liposuction: a case report. Dermatol Surg 2000;26:588-90.
80. Buckley R, Cobb MW, Ghurani S, et al. Mycobacterium fortuitum infection occurring after a punch biopsy procedure. Pediatr Dermatol 1997;14:290-2.
81. Kuritsky JN, Bullen MG, Broome CV, et al. Sternal wound infections and endocarditis due to organisms of the Mycobacterium fortuitum complex. Ann Intern Med 1983;98:938-93.
82. Siegle RJ, Chiaramonti A, Knox DW, et al. Cutaneous candidosis as a complication of facial dermabrasion. J Dermatol Surg Oncol 1984;10:891-5.
83. Giandoni MB, Grabski WJ. Cutaneous candidiasis as a cause of delayed surgical wound healing. J Am Acad Dermatol 1994;30:981-4.
84. Nanni CA, Alster TS. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients. Dermatol Surg 1998;24:315-20.
85. Trizna Z, Chen SH, Lockhart S, et al. Candida parapsilosis chrondritis successfully treated with oral fluconazole. Arch Dermatol 2000;136:804.
86. Isaac M. Cutaneous aspergillosis. Dermatol Clin 1996;14:137-40.
87. Van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol 1998;36:3115-21.
88. Elewski BE, Radentz WH, Gupta AK. Opportunistic mycoses. In: Elewski BE, editor. Cutaneous fungal infections. 2nd edition. Malden (MA): Blackwell Science; 1998. p. 225-59.
89. Lai CS, Lin SD, Chou CK, et al. Aspergillosis complicating the grafted skin and free muscle flap in a diabetic. Plast Reconstr Surg 1993;92:532-6.
90. Anderson LL, Giandoni MB, Keller RA, et al. Surgical wound healing complicated by Aspergillus infection in a nonimmunocompromised host. Dermatol Surg 1995;21:799-801.
91. Bryce EA, Walker M, Scharf S, et al. An outbreak of cutaneous aspergillosis in a tertiary-care hospital. Infect Control Hosp Epidemiol 1996;17:170-2.
92. Kerdel-Vegas F, Harman R, Kerdel F, et al. Protozoan Infections II. In: Canizares O, Harman R, editors. Clinical tropical dermatology. 2nd edition. Boston (MA): Blackwell Scientific; 1992. p. 293-323.
93. Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9.
94. Grevelink SA, Lerner EA. Leishmaniasis. J Am Acad Dermatol 1996;34:257-72.
95. Wortmann GW, Aronson NE, Miller RS, et al. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis 2000;31:199-201.
96. Czechowicz RT, Millard TP, Smith HR, et al. Reactivation of cutaneous leishmaniasis after surgery. Br J Dermatol 1999;141:1113-6.
97. McWhinney PH, Mir N, Love WC, et al. Cutaneous leishmaniasis presenting as a postoperative granuloma. J R Soc Med 1993;86:236-7.
98. Lemons-Estes FM, Neafie RC, Meyers WM. Unusual cutaneous infections and parasitic diseases. Dermatol Clin 1999;17:151-85.
99. Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 1998;27:1457-64.
100. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.
101. Llanos-Cuentas A, Echevarria J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997;25:677-84.
102. Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992;165:528-34.
103. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990;69:19-36.
104. Brown TJ, Vander Straten M, Tyring SK. Antiviral agents. Dermatol Clin 2001;19:23-34.
105. Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999;25:242-6.
106. Waldorf HA, Kauvar AN, Geronemus RG. Skin resurfacing of fine to deep rhytides using a char-free carbon dioxide laser in 47 patients. Dermatol Surg 1995;21:940-6.
107. Dzubow LM. Scarring following herpes simplex infection of postsurgical cutaneous sites. J Dermatol Surg Oncol 1989;15:65-70.
108. Perkins SW, Sklarew EC. Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area. Plast Reconstr Surg 1996;98:427-33.
109. Silverman AK, Laing KF, Swanson NA, et al. Activation of herpes simplex following dermabrasion. Report of a patient successfully treated with intravenous acyclovir and brief review of the literature. J Am Acad Dermatol 1985;13:103-8.
110. Rapaport MJ, Kamer F. Exacerbation of facial herpes simplex after phenolic face peels. J Dermatol Surg Oncol 1984;10:57-8.
111. Langenberg AG, Corey L, Ashley RL. A prospective study of new infections with herpes simplex virus type 1 and type 2. N Engl J Med 1999;341:1432-8.